![]() | |
Names | |
---|---|
Preferred IUPAC name
5-[3-(1-Methylcyclopropyl)propyl]-2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-trione | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C14H16N2O4 | |
Molar mass | 276.292 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.[1]
References
[edit]- ^ Palani, Anandan (November 2011). "Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia". ACS Medicinal Chemistry Letters. 3 (1): 63–8. doi:10.1021/ml200243g. PMC 4025820. PMID 24900372.